REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of ...

BDC-3042 demonstrated a favorable safety profile, with no dose-limiting toxicities or serious drug-related adverse events reported, which is significant for advancing clinical development. The drug ...

BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid ...

View today's TXC Corp stock price and latest 3042 news and analysis. Create real-time notifications to follow any changes in the live stock price.

Assess whether 3042 fits your portfolio by analysing key metrics including dividend yield (where relevant), expense ratio, holdings composition and long-term performance trends. Compare asset ...